• A pharmaceutical company based in Boston aimed to speed up their target discovery and validation process for inflammatory disease using single-cell RNA-seq data.
• Elucidata systematically addressed this challenge by leveraging curated data on Polly and their expertise in analyzing single-cell RNA-seq data.
• This resulted in the identification of four new targets and the validation of five pre-identified targets.
• The pharma achieved a four-fold acceleration in target identification and validation with the help of this partnership.

‍